Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma

JCO Precis Oncol. 2017:2017:PO.17.00034. doi: 10.1200/PO.17.00034. Epub 2017 Aug 18.

¹ Department of Pediatrics, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College.
² Professor Dr. Obayedullah Ferdousi Foundation Cancer Hospital and Research Institute.
³ Avon-MGH Global Breast Cancer Research Program, Massachusetts General Hospital.
⁴ The Sidney Kimmel Comprehensive Cancer Institute at Johns Hopkins.
⁵ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College.
⁶ New York Genome Center.
⁷ Department of Social Work, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College.
⁸ Department of Radiology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College.
⁹ Department of Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College.
¹⁰ Rockefeller University.
¹¹ Howard Hughes Medical Institute.
¹² Loxo Oncology.
¹³ Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College.

No abstract available

Keywords: Targeted therapy; cancer genomics; global health; larotrectinib; pediatric cancer; secretory breast carcinoma.

Grants and funding